T. Rowe Price Associates’s OncoSec Medical Incorporated ONCS Stock Holding History

T. Rowe Price Associates’s Portfolio ONCS Stock Details ONCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-518	Closed	-$54K	–	2996
2021 Q1	$54K	Hold	518	–	–	﹤0.01%	2822
2020 Q4	$74K	Sell	518 -257	-33%	-$27.4K	﹤0.01%	2638
2020 Q3	$58K	Buy	+775	New	+$60.4K	﹤0.01%	2541
2019 Q2	–	Sell	-257	Closed	-$32K	–	2578
2019 Q1	$32K	Hold	257	–	–	﹤0.01%	2514
2018 Q4	$36K	Sell	257 -441	-63%	-$111K	﹤0.01%	2537
2018 Q3	$215K	Hold	698	–	–	﹤0.01%	2445
2018 Q2	$212K	Buy	698 +257	+58%	+$90.1K	﹤0.01%	2444
2018 Q1	$182K	Hold	441	–	–	﹤0.01%	2435
2017 Q4	$158K	Buy	+441	New	+$154K	﹤0.01%	2455

Other funds holding ONCS

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

T. Rowe Price Associates's ONCS Position: Q2 2021 in Review

T. Rowe Price Associates sold out of OncoSec Medical Incorporated (ONCS) in Q2 2021, closing a stake of 518 shares — an estimated $54K sold.

T. Rowe Price Associates first reported a position in ONCS in Q4 2017 and held it in 9 quarters. The position peaked at $215K in Q3 2018. 35 funds tracked by Wall St. Rank hold ONCS as of Q2 2021.

T. Rowe Price Associates reported no remaining OncoSec Medical Incorporated position as of Q2 2021 after selling out during the quarter.
T. Rowe Price Associates sold 518 OncoSec Medical Incorporated shares in Q2 2021, an estimated $54K.
T. Rowe Price Associates first reported a position in OncoSec Medical Incorporated in Q4 2017 and held it in 9 quarters.
T. Rowe Price Associates's OncoSec Medical Incorporated position peaked at $215K in Q3 2018.
35 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q2 2021.

Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.